Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 5/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21256815 | 0.82 | SOS1 (0.39) | KCNQ3KCNQ2MAP3K12MTORPIK3CA | |
| SCHEMBL12082429 | 0.82 | SOS1 (0.39) | KCNQ3KCNQ2MAP3K12MTORPIK3CA | |
| SCHEMBL21256819 | 0.82 | SOS1 (0.39) | KCNQ3KCNQ2MAP3K12MTORPIK3CA | |
| SCHEMBL30206581 | 0.79 | MAP3K12 (0.39) | MAP3K12MTORPIK3CAPRKDCSYK | |
| SCHEMBL15399356 | 0.79 | MAP3K12 (0.44) | MAP3K12MTORPIK3CAPRKDCSOS1 | |
| SCHEMBL19221771 | 0.79 | MAP3K12 (0.44) | MAP3K12MTORPIK3CAPRKDCSOS1 | |
| SCHEMBL30206213 | 0.79 | MAP3K12 (0.39) | MAP3K12MTORPIK3CAPRKDCSYK | |
| SCHEMBL15399039 | 0.79 | MAP3K12 (0.44) | MAP3K12MTORPIK3CAPRKDCSOS1 | |
| SCHEMBL25889732 | 0.79 | MAP3K12 (0.39) | MAP3K12MTORPIK3CAPRKDCSYK | |
| SCHEMBL25889731 | 0.79 | MAP3K12 (0.39) | MAP3K12MTORPIK3CAPRKDCSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | KCNQ3 1860/4885KCNQ2 1429/4885MAP3K12 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.